Psychedelics Companies Are Skyrocketing

Three weeks ago, I wrote to you about some important movements happening in psychedelics companies.

Most importantly, the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) just released positive Phase 3 trial data for MDMA therapy for treating PTSD.

MAPS’ mission is to commercialize prescription psychedelics so we can use them alongside traditional therapies.

This is the second positive trial the company has submitted, and it’s now working on another.

According to financial news site Proactive…

The study showed that MDMA-assisted therapy resulted in 86.5% of participants experiencing a clinically meaningful improvement in their PTSD symptoms at 18 weeks post-baseline, compared to 69% in the placebo with therapy group. 

It also showed that 71.2% of participants who received MDMA-assisted therapy compared to 47.6% of participants who received a placebo plus therapy no longer met the DSM-5 diagnostic criteria for PTSD at the end of the study.

This is extremely positive news for MDMA treatment, which has further bolstered the talk around psychedelics in general.

And it’s not being used just to treat symptoms like the drugs that Big Pharma creates. It’s actually eliminating PTSD long term, in some cases.

According to Psychedelic Spotlight, MAPS founder and president Rick Doblin said, "MDMA-assisted therapy for PTSD is on track to be considered for approval by the FDA in 2024.” And Payton Nyquvest, CEO of Numinus — a psychedelic medicine company — told the company that this “represents a significant milestone not just for the health care and psychedelic industries, but also for humanity as a whole.”

Researchers said about the study, “Not only is MDMA-assisted therapy efficacious in individuals with severe PTSD, but it may also provide improved patient safety. Compared with current first-line pharmacological and behavioral therapies, MDMA-assisted therapy has the potential to dramatically transform treatment for PTSD and should be expeditiously evaluated for clinical use.”

Other drivers of interest in the space include the 2018 bestseller How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence, which was turned into a hit Netflix series this year.

And Joe Rogan, who reaches millions of people each day, has recently hosted multiple experts on psychedelics, including Rick Doblin, the founder of MAPS.

Keep an eye on MAPS, as the company is doing big things. It describes itself as a “non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.”

Over the last six months, the mainstream press has even started to cover the subject, which would have been unheard-of just a few years ago. CNBC, Forbes, InvestorPlace, and The Wall Street Journal have all run stories about psychedelics.

Helping boost the momentum are high-net-worth individuals like Elon Musk publicly supporting magic mushrooms.

And just this week, it was revealed on social media that Steve Cohen, hedge fund manager and New York Mets owner, purchased nearly 19 million shares of Cybin (NYSE: CYBN) through his Point72 Asset Management hedge fund.

Cybin charged 40% higher on the news.

It's great to see this kind of interest because for a long time, we only had anecdotal evidence that psychedelics helped people get a better understanding of how the world works and a better sense of self, which allowed many to shrug off depressive states.

However, it’s no longer just anecdotal evidence supporting the health benefits of psychoactive compounds. Studies are showing that compounds like psilocybin help new brain cells form connections with older brain cells. This means psilocybin helps with neuroplasticity, or the ability of the brain to change, grow, and evolve through life experiences. This is why many are lauding mushrooms as a healing drug.

Psilocybin is being studied as a treatment for depression, anxiety, alcoholism, smoking cessation, and cancer-related distress. Shrooms are also being used by tech entrepreneurs as a “designer drug.” Millionaires are saying microdosing shrooms (taking a very small amount) gives them an edge over the competition.

Here’s why you need to be looking at the companies now, before it's too late…

We’ve got a new class of drugs that are going through regulatory testing as we speak and whose negative stigma is going away.

They can be used in virtually every area of a person’s health: mental health, pain, performance…

This is set to grow into a trillion-dollar industry in the next five years — probably much sooner.

It represents the opposite industry as weed. Weed came in as a health play, but ultimately failed and is primarily being used recreationally.

Some are saying investing in the space now is like buying pharma in the 1920s or the internet in the 1990s.

Only time will tell.

Here’s what I predicted in my last editorial about the psychedelic industry.

It’s a big industry. According to the NIH, 5% of adults have PTSD in any given year and more than 8% of U.S. adults have experienced a depressive episode.

Right now we’re excruciatingly close to some of these drugs being FDA approved.

The closest is MDMA for its ability to treat PTSD.

The catalysts for upside growth include clinical trial data from MAPS and a possible FDA approval of MDMA.

For now, I want to leave you with the top stocks in the space.

Well, now that’s even closer to reality.

And some of the top stocks I mentioned have been skyrocketing.

As I wrote above, Steven Cohen's investment has put a much-needed bottom in the industry, and we should see much more institutional investment here soon.

If you want to know my No. 1 psychedelic pick, sign up for risk-free access to my model portfolio.

You won't be disappointed. 

Stay frosty,

Alexander Boulden
Editor, Wealth Daily

Check us out on YouTube!

After Alexander’s passion for economics and investing drew him to one of the largest financial publishers in the world, where he rubbed elbows with former Chicago Board Options Exchange floor traders, Wall Street hedge fund managers, and International Monetary Fund analysts, he decided to take up the pen and guide others through this new age of investing.

Alexander is the investment director of Insider Stakeout — a weekly investment advisory service dedicated to tracking the smartest money on the planet so that his readers can achieve life-altering, market-beating returns. He also serves at the managing editor for R.I.C.H. Report, a comprehensive service that uses the highest-quality investment research and strategies that guides its members in growing their wealth on top of preserving it.

Check out his editor’s page here.

Want to hear more from Alexander? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.